Drugs / Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant
Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00073216 | ? → Sep 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00073216 ↗ |
| Modality | Vaccine | “Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant Vaccine” NCT00073216 ↗ |